Theramex has grown to become a global pharmaceutical company dedicated to Women’s Health in over eighty countries, across five continents.
Theramex is acquired by PAI and Carlyle from CVC Capital Partners. Both companies utilize their deep sector experience within healthcare to support Theramex’s growth trajectory.
Theramex plans 3 additional global launches and an expansion of their direct presence into 6 additional markets in Europe and Latin America. Theramex will serve over 80 markets to offer practical and dependable solutions for all women
Theramex opens another HQ in Warsaw, Poland.
It also awards five grants to fund research into Assisted Reproductive Medicine
With a presence in key countries including the UK, France, Germany, Italy, Spain and Australia, Theramex expands its reach into The Netherlands, Poland, Slovakia and Romania. In June, Theramex completed separation from Teva in all EU markets
Teva Women’s Health is sold to CVC Capital Partners. Theramex emerges as an independent company dedicated to creating important treatments in Women’s Health
Theramex enters the contraception market with the introduction of a new product. Over the next few years, Theramex develops its product range and expands its portfolio, serving women’s needs in over 50 markets
Teva Pharmaceuticals acquires Theramex and introduces the Teva Women’s Health brand
Merck KGaA acquires Theramex. The company footprint grows to serve over 25 countries
Merck acquires Theramex from François Rougaignon, Paul Hamel Nicolas Guérité and a financial holding company
Theramex has successfully developed a presence in 15 new markets
Theramex grows and expands its menopause product range
The Theramex brand is established as an independent Women’s Health company, mainly serving France and Italy
Theramex is founded by Paul Hamel and based in Monaco